header logo image


Page 1,509«..1020..1,5081,5091,5101,511..1,5201,530..»

Bone marrow drive hopes to help student and save lives

February 16th, 2012 10:17 am

When LSA senior Daniel Lee returned to the United States in December from a family trip to Italy feeling ill, he was rushed to the hospital where he received a life-threatening diagnosis — he had aplastic anemia, a disease that prevents bone marrow from producing red and white blood cells.

Upon hearing news of Lee’s dire need for a bone marrow transplant, students mobilized to encourage members of the campus community to donate marrow and raise awareness about the importance of joining the National Marrow Donor Registry.

As part of this effort, Sigma Kappa sorority members will work with DKMS Americas, a donor recruitment center, helping students, faculty and staff members register for the Be The Match Registry today from 10 a.m. to 4 p.m. in the Anderson AB Room in the Union.

LSA senior Samira Monavvari, Lee’s friend, has been working to promote today’s event via Facebook and has received more than 1,000 confirmed attendees. Monavvari said she hopes to be able to help someone else in need of a transplant, even if she doesn't find a match for Lee.

“The fact that Dan is going through this makes us want to donate to people who we don’t even know because it’s so hard seeing what he’s going through,” Monavvari said.

According to Monavvari, Lee is known jokingly by his friends as “the next Steve Jobs,” adding that he is extremely smart, driven and friendly.

“If you ask him what he wants to do, he’ll always say he wants to be known for something,” Monavvari said. “He is the kind of kid who gets along with everyone … that’s why (his diagnosis) has touched everyone so much.”

LSA junior Jessica Kaltz, a member of Sigma Kappa, started organizing the drive prior to Lee’s diagnosis. Kaltz worked with Christian Montgomery, a University alum and DKMS Americas employee, over the past few months to organize the registry at the University.

She wrote in an e-mail interview that she hopes that Lee’s story will inspire people to attend today’s event.

“When people hear about Dan’s story, I think they will see that by simply taking five minutes of their time by signing up to become a donor, they could possibly be the life-saving difference that Dan needs,” Kaltz wrote.

Montgomery explained that the process for joining the registry involves having potential donors fill out a short form and then submit a cheek swab to determine their tissue type.
Potential donors will then be added to the Be The Match Registry, a national list of potential bone marrow donors.

If the donor is contacted as a match and decides to continue with the process, he or she will be required to take a blood test in order to obtain the best match for the patient in need.

Between four and six weeks later, the donor will undergo a marrow extraction procedure or peripheral blood stem cell donation, depending on the patient’s condition. Contrary to popular belief, the donor typically does not experience significant pain, a common misconception about the two procedures, Montgomery said.

Montgomery is not only a DKMS employee, but also a bone marrow donor himself. In 2007, he registered at an event in the Diag, and in January 2008 he was contacted as a potential match for a 22-year-old female in New Jersey suffering from paroxysmal nocturnal hemoglobinuria, a rare blood disease.

Nicole Mausteller, the patient to whom Montgomery made his donation, said her disorder was discovered through blood work that was required as part of the process of becoming a dental assistant.

Montgomery donated through marrow extraction in May 2008, a procedure that he said left him a bit stiff and sore for a few days. After receiving a one-month, six-month and one-year update, Montgomery and Mausteller agreed to exchange contact information. They have been in contact since February 2010 and remain good friends.

“He’s my hero,” Mausteller said.

Read more here:
Bone marrow drive hopes to help student and save lives

Read More...

Stem Cell Stocks Skyrocket in 2012 — Cytori Therapeutics and Cord Blood America on the Upswing

February 16th, 2012 10:16 am

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cytori Therapeutics, Inc. (NASDAQ: CYTX - News) and Cord Blood America, Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

http://www.paragonreport.com/CYTX

http://www.paragonreport.com/CBAI

Shares of Cytori Therapeutics have skyrocketed nearly 70 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care.

In late January, Cytori received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the "ATHENA" trial. ATHENA will investigate the use of the Celution System to treat a form of coronary heart disease, chronic myocardial ischemia (CMI).

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cord Blood America, Inc. is a holding company that, through its subsidiaries, is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in stem cell therapy.

USA Today recently reported that umbilical cord blood stem cells have been successfully used to treat individuals with type 1 diabetes, highlighting the importance of storing stem cells at birth. The USA Today article says that stem cells from cord blood have been used to "reeducate" the immune system T cells of people with type 1 diabetes so their pancreas started producing insulin again - thereby reducing the amount of insulin they needed to inject.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Link:
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing

Read More...

Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications

February 16th, 2012 3:45 am

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/fc9dd6/primary_and_stem_c) has announced the addition of John Wiley and Sons Ltd's new book "Primary and Stem Cells: Gene Transfer Technologies and Applications" to their offering.

This book describes basic cell engineering methods, emphasizing stem cell applications, and use of the genetically modified stem cells in cell therapy and drug discovery. Together, the chapters introduce and offer insights on new techniques for engineering of stem cells and the delivery of transgenes into stem cells via various viral and non-viral systems. The book offers a guide to the types of manipulations currently available to create genetically engineered stem cells that suit any investigator's purpose, whether it's basic science investigation, creation of disease models and screens, or cells for therapeutic applications.

Key Topics Covered:

PART I: CLONING AND GENE DELIVERY

1. DNA Assembly Technologies Based on Homologous Recombination

2. Multigene Assembly for Construction of Synthetic Operons: Creation and Delivery of an Optimized All-IN-One Expression Construct for Generating Mouse iPS Cells

3. Strategies for the Delivery of Naked DNA

PART II: NONINTEGRATING TECHNOLOGIES

4. Episomal Vectors

5. Nonintegrating DNA Virus

6. Nonintegrating RNA Viruses

7. Protein Delivery

PART III: INTEGRATING TECHNOLOGIES

8. Sleeping Beauty Transposon-Mediated Stable Gene Delivery

9. Integrating Viral Vectors for Gene Modifications

10. Bacteriophage Integrases for Site-Specific Integration

11. Improving Gene Targeting Efficiency in Human Pluripotent Stem Cells

PART IV: APPLICATIONS

12. Modified Stem Cells as Disease Models and in Toxicology Screening

13. Screening and Drug Discovery

INDEX

Author:

UMA LAKSHMIPATHY is a principal investigator at Life Technologies. She has a PhD in life sciences, with academic and industry experience in molecular biology and stem cells. Dr. Lakshmipathy holds four patents and has authored more than forty publications.

BHASKAR THYAGARAJAN is a program manager at Life Technologies. He has a PhD in pharmacology, with expertise in the areas of molecular biology, DNA recombination, gene and cell therapy, and protein purification. He holds one patent and has authored more than twenty publications.

For more information visit http://www.researchandmarkets.com/research/fc9dd6/primary_and_stem_c

More here:
Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications

Read More...

Hot nanotubes blast chemo-resistant breast cancer cells into oblivion

February 16th, 2012 3:45 am

These cancer stem cells are difficult to kill because they don't divide rapidly--a common behavior that most cancer treatments target.

When it comes to cancer cells, a particularly confounding breed called cancer stem cells have proven difficult to kill. Because they divide so slowly, chemo drugs do them little harm, and they appear resistant to heat therapies that are generally good at killing most cells. Some cancer drugs even appear to promote the growth of cancer stem cells.

Suzy V. Torti

(Credit: Wake Forest Baptist Medical Center)

Now, three years after they found that the heat from 30-second laser blasts can kill kidney cancer stem cells, researchers at Wake Forest Baptist Medical Center say the same treatment works to kill breast cancer stem cells as well.

Torti's team tested this photothermal therapy on mice, injecting tumors containing breast cancer stem cells with nanotubes that in and of themselves have no anti-tumor properties. When exposed to 30 seconds of laser light from outside the body, however, those nanotubes vibrated and produced sufficient heat to stop the growth of the entire tumor bulk, including the cancer stem cells.

"[Cancer stem cells] are tough," says lead investigator and biochemistry professor Suzy V. Torti. "The advantage of the nanotube approach is that in addition to eliminating the tumor bulk, it would get rid of the stem cells, so presumably these tumors would be less likely to recur than tumors that were treated with something else, like drugs or radiation."

Torti says that while this study only validates this new type of therapy on breast cancer specifically, it may work on other types of cancer stem cells as well. Many questions about how the heat kills the cells remain, however, and she says it will probably take a good five to 10 years of further study before they can investigate the therapy in human clinical trials.

For now, Torti says that the early success of this approach, detailed in the April 2012 issue of the journal Biomaterials, "gives us a direction to go for a cure." Maybe some day it could serve as a non-invasive alternative to surgically removing certain types of malignant tumors.

View original post here:
Hot nanotubes blast chemo-resistant breast cancer cells into oblivion

Read More...

Hot nanotubes blast chemo-resistant cancer cells into oblivion

February 16th, 2012 3:45 am

These cancer stem cells are difficult to kill because they don't divide rapidly--a common behavior that most cancer treatments target.

When it comes to cancer cells, a particularly confounding breed called cancer stem cells have proven difficult to kill. Because they divide so slowly, chemo drugs do them little harm, and they appear resistant to heat therapies that are generally good at killing most cells. Some cancer drugs even appear to promote the growth of cancer stem cells.

Suzy V. Torti

(Credit: Wake Forest Baptist Medical Center)

Now, three years after they found that the heat from 30-second laser blasts can kill kidney cancer stem cells, researchers at Wake Forest Baptist Medical Center say the same treatment works to kill breast cancer stem cells as well.

Torti's team tested this photothermal therapy on mice, injecting tumors containing breast cancer stem cells with nanotubes that in and of themselves have no anti-tumor properties. When exposed to 30 seconds of laser light from outside the body, however, those nanotubes vibrated and produced sufficient heat to stop the growth of the entire tumor bulk, including the cancer stem cells.

"[Cancer stem cells] are tough," says lead investigator and biochemistry professor Suzy V. Torti. "The advantage of the nanotube approach is that in addition to eliminating the tumor bulk, it would get rid of the stem cells, so presumably these tumors would be less likely to recur than tumors that were treated with something else, like drugs or radiation."

Torti says that while this study only validates this new type of therapy on breast cancer specifically, it may work on other types of cancer stem cells as well. Many questions about how the heat kills the cells remain, however, and she says it will probably take a good five to 10 years of further study before they can investigate the therapy in human clinical trials.

For now, Torti says that the early success of this approach, detailed in the April 2012 issue of the journal Biomaterials, "gives us a direction to go for a cure." Maybe some day it could serve as a non-invasive alternative to surgically removing certain types of malignant tumors.

View original post here:
Hot nanotubes blast chemo-resistant cancer cells into oblivion

Read More...

Linsanity Takes White Plains; The Twilight of Jim Calhoun

February 16th, 2012 3:45 am

Today in sports: The Knicks guard is moving to Westchester, despite our warnings, health problems and the always capricious NCAA have this looking like the final spring for one of college basketball's greatest coaches, and Kobe Bryant may not have to pay that $75 million divorce settlement after all.

RELATED: A Slightly Cheaper Super Bowl Ticket; Possible New Teams for Peyton Manning

New York Knicks point guard Jeremy Lin has reportedly ignored our advice and reached a deal to sublet a two-bedroom apartment in the Trump Tower in White Plains. We still say he should have stayed in the city, but the New York Daily News points out the building is "home to several other Knicks players and some New York Rangers as well," so he won't get  too lonely. Lin is now the third Knick to occupy this particular apartment. Much beloved former Knicks forward David Lee -- now a member of the Golden State Warriors -- owns it, and center Amar'e Stoudemire briefly rented it from him during last year's NBA lockout, before coming to the not-unreasonable conclusion it was inefficient to have an apartment in White Plains and a $37,500-a-month penthouse in the city. New York real estate mavens estimate the apartment will cost Lin $3,800 a month, about $800 less than his 8th grade yearbook was being offered for on eBay. [New York Daily News]

RELATED: Don't Tell Injured NFL Players Stem Cell Tourism Is a Bad Idea

Los Angeles Lakers guard Kobe Bryant, who last month agreed to give his wife Vanessa $75 million and three houses as part of a divorce settlement, kissed his future-former-ex at halftime of last night's game against Atlanta. Sources say they're working to repair the relationship. For Kobe, the timing is just great, since the split still needs to be finalized. [TMZ]

RELATED: Say So-Long to the 'Manny Being Manny' Defense

University of Connecticut men's basketball coach Jim Calhoun has won three national titles and beaten cancer three times. But it's looking increasingly unlikely that he's going to return to the sideline again. And really, who can blame him? Earlier this month he took a leave of absence from the team to deal with a spinal conditional called spinal stenosis, that makes both walking and sitting incredibly painful. And last week, the NCAA announced it had denied UConn's request for a waiver that would allow the school to play in the 2013 NCAA Tournament. The school was in violation of a new, vaguely-crooked, very NCAA attempt to raise graduation rates. Per the new rule, "a school must have a two-year average score of 930 or a four-year average of 900 on the NCAA's annual Academic Progress Rate, which measures the academic performance of student athletes." UConn's four-year APR rate was 888.5, With the 2013 ban in place, players are expected to leave for the NBA draft or transfer to other schools in droves, since they won't have to sit out the usual year in-between. That would crater the program's talent base, of course, but University president Susan Herbst -- a supporter of Calhoun's -- seemed to acknowledge the possibility of it happening today, telling USA Today, "I hope they stay, but I don't want to hurt these guys." Calhoun's contract is up in 2014, but the prospect of rebuilding completely from scratch might not be the kind of uphill fight Jim Calhoun--patron saint of college basketball uphill fights -- would enjoy. [USA Today]

RELATED: Albert Pujols Goes West; Another Soccer Match-Fixing Scandal Looms

Monday Night Football will be switching to a two-person booth next season and the odd man out is former Philadelphia Eagles quarterback Ron Jaworski. The pairing of Jaworski and former Oakland Raiders coach Jon Gruden was chaotic, save for the late-game moments where they forget to feign enthusiasm and started giving honest and biting evaluations of what they were seeing. Current play-by-play man Mike Tirico will be back alongside Gruden, which is fantastic if you like  play-by-play broadcasters who will always tell you when the wind knocks a football off a kicking tee, but go entire drives without mentioning the score. [ESPN]

RELATED: Gisele Plays the Super Bowl Blame Game; A Pro Bowl Ultimatum

When it comes to the number of weird, faintly dangerous-seeming neck operations Indianapolis Colts quarterback Peyton Manning has undergone, the accepted number has always been three. Turns out, he may have had four. It's unclear when the fourth procedure happened, though Sports Illustrated's Don Banks places it sometime in a 14 week window last summer. This fourth surgery could explain why Manning is struggling with throws to his left, as well as one made straight and directly in front of his face. front of his face. [Sports Illustrated] 

 

Read the rest here:
Linsanity Takes White Plains; The Twilight of Jim Calhoun

Read More...

Promising early results with therapeutic cancer vaccines

February 16th, 2012 3:43 am

Public release date: 15-Feb-2012
[ | E-mail | Share ]

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, February 15, 2012?Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com). These articles are available free online at http://www.liebertpub.com/cbr

The U.S. FDA recently approved the first cancer therapeutic vaccine for treatment of metastatic prostate cancer. At least 14 other cancer vaccine strategies are in Phase II or III clinical trials for metastatic melanoma, lung cancer, and lymphoma, for example.

A critical perspective, "Recent Advances in Therapeutic Cancer Vaccines," (http://online.liebertpub.com/doi/full/10.1089/cbr.2012.1200) published in the Journal by Jeffrey Schlom, PhD, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD explains that a key advantage of cancer vaccines used in combination with chemotherapy is the extremely low level of toxicity. "The next frontier for vaccine therapy will be the use of vaccines in combination with certain chemotherapeutic agents, radiation, hormone therapy, and certain small molecule targeted therapies," according to Dr. Schlom.

These emerging areas of cancer vaccine therapy are explored in detail in two accompanying research reports by Dr. Schlom's colleagues at NCI/NIH. James Hodge, Hadley Sharp, and Sofia Gameiro describe how a tumor-targeted vaccine can enhance the effectiveness of radiation therapy on cancer growth and spread beyond the primary tumor in the article "Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation." (http://online.liebertpub.com/doi/abs/10.1089/cbr.2012.1202) Drs. Hodge and Gameiro and coauthor Jorge Caballero present the molecular signatures of lung tumor cells that can be made more susceptible to immunotherapy when first exposed to chemotherapeutic agents in the article "Defining the Molecular Signature of Chemotherapy-Mediated Lung Tumor Phenotype Modulation and Increased Susceptibility to T-cell Killing." (http://online.liebertpub.com/doi/abs/10.1089/cbr.2012.1203)

"This perspective and promising research reports are from one of the leading vaccine research laboratories in the world," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. "The ultimate use of cancer vaccines in combination with other immunotherapies, chemotherapy, or radiation therapy will be based on preclinical investigations and hopefully will produce clinical survival benefit for a range of cancers."

###

Cancer Biotherapy and Radiopharmaceuticals, published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways. Complete tables of content and a sample issue may be viewed online at http://www.liebertpub.com/cbr

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research; Human Gene Therapy and Human Gene Therapy Methods; and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at http://www.liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http://www.liebertpub.com
Phone: 914-740-2100
800M-LIEBERT
Fax: 914-740-2101


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Here is the original post:
Promising early results with therapeutic cancer vaccines

Read More...

Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for …

February 16th, 2012 3:42 am

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD).

“We thank Wills Eye Institute once more for providing their IRB and their invaluable contribution to our macular degeneration studies,” said Gary Rabin, ACT’s chairman and CEO. “We are very happy that we can now report that Wills Eye Institute has been approved as a clinical trial site for both our SMD and dry AMD clinical trials. Ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report, the Wills Eye Institute is a truly world-class institution. Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials.”

The Phase I/II trial for SMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Preliminary results relating to both early safety and biological function for the first two patients in the U.S., one SMD patient and one dry AMD patient, were recently reported in The Lancet.

Specific patient enrollment for both trials at the Wills Eye Institute will be determined in the near future. Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on http://www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.

About Stargardt's Disease

Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium.

About hESC-derived RPE Cells

The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

About Wills Eye Institute

Wills Eye Institute is a global leader in ophthalmology, established in 1832 as the nation’s first hospital specializing in eye care. U.S. News & World Report has consistently ranked Wills Eye as one of America’s top three ophthalmology centers since the survey began in 1990. Wills Eye is a premier training site for all levels of medical education. Its resident and post-graduate training programs are among the most competitive in the country. One of the core strengths of Wills is the close connection between innovative research and advanced patient care. Wills provides the full range of primary and subspecialty eye care for improving and preserving sight, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, refractive surgery and retina. Ocular Services include the Wills Laser Correction Center, Low Vision Service, and Diagnostic Center. Its 24/7 Emergency Service is the only one of its kind in the region. Wills Eye also has a network of nine multi-specialty, ambulatory surgery centers throughout the tri-state area. To learn more, please visit http://www.willseye.org.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

Go here to read the rest:
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...

Read More...

Heart Disease: Stem Cells To Toothbrushes

February 16th, 2012 3:42 am

Related To Story


-Dr.Dianne McCallister, Chief Medical Officer at Centuras Porter Adventist Hospital February is heart month, and we are all familiar with exercise and diet to help our hearts. But do you know how stem cells or your toothbrush can help your heart? This week, Lancet published an article on the use of Stem Cells to help repair the heart.Other medical literature shows a link between the health of your teeth and heart disease. What Are Stem Cells? Stem cells are a type of body cell that still has the ability to become any type of tissue. They work in our bodies to help our tissues repair themselves.When stem cells divide, the new cell has the choice to stay a stem cell - or to become a certain type of tissue cell - in this case, were talking about them become heart muscle cells.For years science has been working on the theory that stem cells could be harvested, grown and then used to repair, or grow organs. Healing Damaged Hearts With Stem Cells The researchers at Cedars-Sinai in Los Angeles took 25 patients who had suffered severe heart attacks - 24% of the muscle in the wall of their ventricle - which is the chamber that pumps blood to the body - was scarred and not functioning.These patients had the normal treatment for heart attacks - but also had stem cells harvested from their heart, grown in the lab, and then re- injected into their hearts.Another group of patients with similar heart attacks just received the usual heart treatment.The patients without stem cells did not show any improvement in their heart muscle - but the stem cell patients had about half the injury to their heart reversed - in other words, the scar was dissolved and replaced with functioning heart muscle.This is a very small study, and it is too early to predict when and if this will become a common treatmentThat being said, it is promising that stem cell therapy may have a new promise for heart attack victims.Standard therapy helps the damaged heart function as well as possible while also limiting the chance of another heart attack.This gives hope that we can reverse the damage.However, we need to remember that there is a lot of testing that needs to happen to determine if there are any unwanted side effects of giving stem cells, when it is appropriate to use them, and what long term effects are from using them. Dental Health And Our Hearts There is growing evidence showing that gum disease has an association with heart disease.We know that gum disease - called gingivitis - allows bacteria from our mouth to get into our blood stream.This is somehow related with inflammation and development of blockages in the vessels of the heart.In addition to brushing, we need to be flossing. Using an antiseptic mouth wash daily and regular dental visits to have teeth cleaned is also important.In fact, good dental health habits are associated with a longer life.There are associations between poor dental health and development of such diseases as diabetes, stroke, lung disease and even pre-term births.So the five minutes you spend twice daily on your teeth is an investment in your overall health as wellDr. McCallister is on 7NEWS at 11 a.m. every Wednesday. If you have a topic or question you would like her to discuss, email 11am@thedenverchannel.com. The following are comments from our users. Opinions expressed are neither created nor endorsed by TheDenverChannel.com. By posting a comment you agree to accept our Terms of Use. Comments are moderated by the community. To report an offensive or otherwise inappropriate comment, click the "Flag" link that appears beneath that comment. Comments that are flagged by a set number of users will be automatically removed.

Go here to read the rest:
Heart Disease: Stem Cells To Toothbrushes

Read More...

Stem Cell Stocks: Mending Scarred Hearts

February 16th, 2012 3:41 am

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. This is certainly exciting news considering heart failure is still the No. 1 cause of death in men and women.

The study included 25 heart attack victims, 17 of whom got the stem cell treatment. Those patients saw a 50% reduction in cardiac scar tissue after one year, while the eight control patients saw no improvement.

The procedure involves removing a tiny portion of heart tissue through a needle, cultivating the stem cells from that tissue, and reinserting them in a second minimally invasive procedure, according to Bloomberg.

"If we can regenerate the whole heart, then the patient would be completely normal," said Eduardo Marban, director of Cedars-Sinai Heart Institute who was the study's lead author. "We haven't fulfilled that yet, but we've gotten rid of half of the injury, and that's a good start."

Business section: Investing ideas
Interested in investing in the promise that stem cell therapy holds? For a look at the investing landscape, we compiled a list of the 10 largest companies involved in stem cell therapy.

Do you think this industry will see growth from stem cell research? (Click here to access free, interactive tools to analyze these ideas.)

1. BioTime (NYSE: BTX  ) : Focuses on regenerative medicine and blood plasma volume expanders. Market cap at $291.95M. The company develops and markets research products in the field of stem cells and regenerative medicine. It develops therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases; cardiovascular and blood diseases; therapeutic applications of stem cells to treat orthopedic diseases, injuries, and cancer; and retinal cell product for use in the treatment of age-related macular degeneration.

2. Cleveland BioLabs (Nasdaq: CBLI  ) : Market cap at $111.50M. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines, and Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation.

3. Gentium: Focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. Market cap at $128.29M. The company develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation.

4. Geron (Nasdaq: GERN  ) : Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Market cap at $265.57M. The company has licensing agreement with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

5. Harvard Bioscience: Develops, manufactures, and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities, and government laboratories in the United States and internationally. Market cap at $118.28M. Develops devices used by clinicians and researchers in the field of regenerative medicine, including bioreactors for growing tissue and organs outside the body, and injectors for stem cell therapy.

6. Lydall (NYSE: LDL  ) : Designs and manufactures specialty engineered products for thermal/acoustical, filtration/separation, and bio/medical applications in the United States. Market cap at $163.44M. In addition, it offers Cell-Freeze, a medical device used for cryogenic storage of peripheral blood stem cells.

8. Osiris Therapeutics (Nasdaq: OSIR  ) : Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Market cap at $157.26M. A stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas.

7. Verastem: Market cap at $229.00M. Focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) in breast and other cancers.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.

Kapitall's Alexander Crawford does not own any of the shares mentioned above.

The rest is here:
Stem Cell Stocks: Mending Scarred Hearts

Read More...

Stem cell study in mice offers hope for treating heart attack patients

February 16th, 2012 12:31 am

ScienceDaily (Feb. 15, 2012) — A UCSF stem cell study conducted in mice suggests a novel strategy for treating damaged cardiac tissue in patients following a heart attack. The approach potentially could improve cardiac function, minimize scar size, lead to the development of new blood vessels -- and avoid the risk of tissue rejection.

In the investigation, reported online in the journal PLoS ONE, the researchers isolated and characterized a novel type of cardiac stem cell from the heart tissue of middle-aged mice following a heart attack.

Then, in one experiment, they placed the cells in the culture dish and showed they had the ability to differentiate into cardiomyocytes, or "beating heart cells," as well as endothelial cells and smooth muscle cells, all of which make up the heart.

In another, they made copies, or "clones," of the cells and engrafted them in the tissue of other mice of the same genetic background who also had experienced heart attacks. The cells induced angiogenesis, or blood vessel growth, or differentiated, or specialized, into endothelial and smooth muscle cells, improving cardiac function.

"These findings are very exciting," said first author Jianqin Ye, PhD, MD, senior scientist at UCSF's Translational Cardiac Stem Cell Program. First, "we showed that we can isolate these cells from the heart of middle-aged animals, even after a heart attack." Second, he said, "we determined that we can return these cells to the animals to induce repair."

Importantly, the stem cells were identified and isolated in all four chambers of the heart, potentially making it possible to isolate them from patients' hearts by doing right ventricular biopsies, said Ye. This procedure is "the safest way of obtaining cells from the heart of live patients, and is relatively easy to perform," he said.

"The finding extends the current knowledge in the field of native cardiac progenitor cell therapy," said senior author Yerem Yeghiazarians, MD, director of UCSF's Translational Cardiac Stem Cell Program and an associate professor at the UCSF Division of Cardiology. "Most of the previous research has focused on a different subset of cardiac progenitor cells. These novel cardiac precursor cells appear to have great therapeutic potential."

The hope, he said, is that patients who have severe heart failure after a heart attack or have cardiomyopathy would be able to be treated with their own cardiac stem cells to improve the overall health and function of the heart. Because the cells would have come from the patients, themselves, there would be no concern of cell rejection after therapy.

The cells, known as Sca-1+ stem enriched in Islet (Isl-1) expressing cardiac precursors, play a major role in cardiac development. Until now, most of the research has focused on a different subset of cardiac progenitor, or early stage, cells known as, c-kit cells.

The Sca-1+ cells, like the c-kit cells, are located within a larger clump of cells called cardiospheres.

The UCSF researchers used special culture techniques and isolated Sca-1+ cells enriched in the Isl-1expressing cells, which are believed to be instrumental in the heart's development. Since Isl-1 is expressed in the cell nucleus, it has been difficult to isolate them but the new technique enriches for this cell population.

The findings suggest a potential treatment strategy, said Yeghiazarians. "Heart disease, including heart attack and heart failure, is the number one killer in advanced countries. It would be a huge advance if we could decrease repeat hospitalizations, improve the quality of life and increase survival." More studies are being planned to address these issues in the future.

An estimated 785,000 Americans will have a new heart attack this year, and 470,000 who will have a recurrent attack. Heart disease remains the number one killer in the United States, accounting for one out of every three deaths, according to the American Heart Association.

Medical costs of cardiovascular disease are projected to triple from $272.5 billion to $818.1 billion between now and 2030, according to a report published in the journal Circulation.

First author Ye, Henry Shih, Richard E. Sievers, Yan Zhang, and Megha Prasad are with the UCSF Division of Cardiology; Yeghiazarians and Andrew Boyle are with the UCSF Division of Cardiology and the UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research; William Grossman is with the UCSF Division of Cardiology and the UCSF Cardiovascular Research Institute; Harold S. Bernstein is with the UCSF Cardiovascular Research Institute, the UCSF Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, and the UCSF Department of Pediatrics; Hua Su is with UCSF Department of Anesthesia and Perioperative Care; and Yan Zhou with the UCSF Department of Cell and Tissue Biology.

The study was supported by funds from the Wayne and Gladys Valley Foundation, the UCSF Cardiac Stem Cell Fund and the Harold Castle Foundation.

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of California, San Francisco (UCSF), via Newswise. The original article was written by Leland Kim.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Jianqin Ye, Andrew Boyle, Henry Shih, Richard E. Sievers, Yan Zhang, Megha Prasad, Hua Su, Yan Zhou, William Grossman, Harold S. Bernstein, Yerem Yeghiazarians. Sca-1 Cardiosphere-Derived Cells Are Enriched for Isl1-Expressing Cardiac Precursors and Improve Cardiac Function after Myocardial Injury. PLoS ONE, 2012; 7 (1): e30329 DOI: 10.1371/journal.pone.0030329

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Link:
Stem cell study in mice offers hope for treating heart attack patients

Read More...

Stem Cell Stocks Skyrocket in 2012 — Cytori Therapeutics and Cord Blood America on the Upswing

February 16th, 2012 12:31 am

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Cytori Therapeutics, Inc. (NASDAQ: CYTX - News) and Cord Blood America, Inc. (OTC.BB: CBAI.OB - News). Access to the full company reports can be found at:

http://www.paragonreport.com/CYTX

http://www.paragonreport.com/CBAI

Shares of Cytori Therapeutics have skyrocketed nearly 70 percent year-to-date. The company develops, manufactures, and sells medical products and devices to enable the practice of regenerative medicine. The Company's technology is the Celuion family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care.

In late January, Cytori received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the "ATHENA" trial. ATHENA will investigate the use of the Celution System to treat a form of coronary heart disease, chronic myocardial ischemia (CMI).

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cord Blood America, Inc. is a holding company that, through its subsidiaries, is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in stem cell therapy.

USA Today recently reported that umbilical cord blood stem cells have been successfully used to treat individuals with type 1 diabetes, highlighting the importance of storing stem cells at birth. The USA Today article says that stem cells from cord blood have been used to "reeducate" the immune system T cells of people with type 1 diabetes so their pancreas started producing insulin again - thereby reducing the amount of insulin they needed to inject.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

Read the rest here:
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing

Read More...

Bone Repair Stem Cell Breakthrough Shows Promise

February 16th, 2012 12:31 am

Editor's Choice
Main Category: Stem Cell Research
Article Date: 15 Feb 2012 - 8:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public:

5 (3 votes)

Healthcare Prof:
According to a study published in the February issue of the STEM CELL Translational Medicine Journal , a world-first technique for generating adult stem cells (mesenchymal stem cells [MSCs]) has been developed by researchers at the University of Queensland. This new method can be used to repair bone and possibly other organs, and will considerably affect individuals suffering from a variety of serious diseases.

Professor Nicholas Fisk, who leads the collaborative study between the UQ Clinical Research Center (UQCCR) and the UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN), explained:

"We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature.

The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumors.

Because only small numbers of MSCs exist in the bone marrow, and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

Ernst Wolvetang, co-researcher on the study and AIBN Associate Professor, explained that the technique had overcome a considerable obstacle in the translation of stem cell-based therapy.

Wolvetang said: "We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN."

Written by: Grace Rattue

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our stem cell research section for the latest news on this subject. UniQuest, The University of Queensland's main commercialization company, invites parties interested in licensing the intellectual property relating to this discovery to contact UniQuest on 3365 4037 or lifesciences@uniquest.com.au.

Source: University of Queensland

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Grace Rattue. "Bone Repair Stem Cell Breakthrough Shows Promise." Medical News Today. MediLexicon, Intl., 15 Feb. 2012. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/articles/241706.php&gt;

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Continue reading here:
Bone Repair Stem Cell Breakthrough Shows Promise

Read More...

Stem Cell Stocks: Mending Scarred Hearts

February 16th, 2012 12:31 am

A new study at Johns Hopkins University has shown that stem cells from patients' own cardiac tissue can be used to heal scarred tissue after a heart attack. This is certainly exciting news considering heart failure is still the No. 1 cause of death in men and women.

The study included 25 heart attack victims, 17 of whom got the stem cell treatment. Those patients saw a 50% reduction in cardiac scar tissue after one year, while the eight control patients saw no improvement.

The procedure involves removing a tiny portion of heart tissue through a needle, cultivating the stem cells from that tissue, and reinserting them in a second minimally invasive procedure, according to Bloomberg.

"If we can regenerate the whole heart, then the patient would be completely normal," said Eduardo Marban, director of Cedars-Sinai Heart Institute who was the study's lead author. "We haven't fulfilled that yet, but we've gotten rid of half of the injury, and that's a good start."

Business section: Investing ideas
Interested in investing in the promise that stem cell therapy holds? For a look at the investing landscape, we compiled a list of the 10 largest companies involved in stem cell therapy.

Do you think this industry will see growth from stem cell research? (Click here to access free, interactive tools to analyze these ideas.)

1. BioTime (NYSE: BTX  ) : Focuses on regenerative medicine and blood plasma volume expanders. Market cap at $291.95M. The company develops and markets research products in the field of stem cells and regenerative medicine. It develops therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases; cardiovascular and blood diseases; therapeutic applications of stem cells to treat orthopedic diseases, injuries, and cancer; and retinal cell product for use in the treatment of age-related macular degeneration.

2. Cleveland BioLabs (Nasdaq: CBLI  ) : Market cap at $111.50M. Its products include Protectan CBLB502, a radioprotectant molecule with multiple medical and defense applications for reducing injury from acute stresses, such as radiation and chemotherapy by mobilizing various natural cell protecting mechanisms, including inhibition of apoptosis, reduction of oxidative damage, and induction of factors that induce protection and regeneration of stem cells in bone marrow and the intestines, and Protectan CBLB612, a modified lipopeptide mycoplasma that acts as a stimulator and mobilizer of hematopoietic stem cells to peripheral blood, providing hematopoietic recovery during chemotherapy and during donor preparation for bone marrow transplantation.

3. Gentium: Focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. Market cap at $128.29M. The company develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation.

4. Geron (Nasdaq: GERN  ) : Develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. Market cap at $265.57M. The company has licensing agreement with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

5. Harvard Bioscience: Develops, manufactures, and markets apparatus and scientific instruments used in life science research in pharmaceutical and biotechnology companies, universities, and government laboratories in the United States and internationally. Market cap at $118.28M. Develops devices used by clinicians and researchers in the field of regenerative medicine, including bioreactors for growing tissue and organs outside the body, and injectors for stem cell therapy.

6. Lydall (NYSE: LDL  ) : Designs and manufactures specialty engineered products for thermal/acoustical, filtration/separation, and bio/medical applications in the United States. Market cap at $163.44M. In addition, it offers Cell-Freeze, a medical device used for cryogenic storage of peripheral blood stem cells.

8. Osiris Therapeutics (Nasdaq: OSIR  ) : Focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas. Market cap at $157.26M. A stem cell company, focuses on the development and marketing of therapeutic products to treat various medical conditions in the inflammatory, autoimmune, orthopedic, and cardiovascular areas.

7. Verastem: Market cap at $229.00M. Focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) in breast and other cancers.

Interactive Chart: Press Play to compare changes in analyst ratings over the last two years for the stocks mentioned above. Analyst ratings sourced from Zacks Investment Research.

Kapitall's Alexander Crawford does not own any of the shares mentioned above.

Read the original post:
Stem Cell Stocks: Mending Scarred Hearts

Read More...

Favorable News From Advanced Cell Technology and StemCells Inc Boosts Optimism in Regenerative Medicine Industry

February 16th, 2012 12:31 am

NEW YORK, NY--(Marketwire -02/15/12)- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem Cell Stocks index (RXSTM) has returned more than 20 percent, as favorable news from some of stem cell industry heavyweights has boosted investor optimism in the sector. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Advanced Cell Technology, Inc. (OTC.BB: ACTC.OB - News) and StemCells Inc. (NASDAQ: STEM - News). Access to the full company reports can be found at:

http://www.paragonreport.com/ACTC

http://www.paragonreport.com/STEM

Shares of StemCells Inc. have skyrocketed nearly 20 percent year-to-date. StemCells Inc. is focused on cellular medicine, or the use of stem and progenitor cells as the basis for therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development.

Earlier this month the company released a statement saying that it received U.S. Food and Drug Administration authorization to start a clinical trial of the company's potential treatment for dry age-related macular degeneration, or AMD. AMD is the leading cause of vision loss and blindness in people over 55 years old and about 30 million people worldwide are affected by the disease, the company said

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at http://www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Shares of Advanced Cell Technology are up more than 30 percent this year - although they are down more than 20 percent over the last month. Advanced Cell Technology has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research.

Earlier this week Advanced Cell Technology announced that a third patient has been treated for Stargardt's macular dystrophy in its US. Phase I/II clinical trial. The therapy uses retinal pigment epithelial cells derived from human embryonic stem cells. Stargardt's disease or Stargardt's Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer

See the original post here:
Favorable News From Advanced Cell Technology and StemCells Inc Boosts Optimism in Regenerative Medicine Industry

Read More...

Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for …

February 16th, 2012 12:31 am

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the company’s Phase I/II clinical trial for Stargardt’s Macular Dystrophy (SMD), a form of juvenile macular degeneration, using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. Earlier this year, the Company also announced that the IRB at Wills Eye Institute had approved the participation of the institution as a site for ACT’s clinical trial for dry age-related macular degeneration (dry AMD).

“We thank Wills Eye Institute once more for providing their IRB and their invaluable contribution to our macular degeneration studies,” said Gary Rabin, ACT’s chairman and CEO. “We are very happy that we can now report that Wills Eye Institute has been approved as a clinical trial site for both our SMD and dry AMD clinical trials. Ranked as one of the best ophthalmology hospitals in the country by U.S. News & World Report, the Wills Eye Institute is a truly world-class institution. Our team is eagerly anticipating working with Dr. Carl Regillo, a renowned retinal surgeon and director of clinical retina research at Wills Eye Institute, as well as a professor of ophthalmology at Thomas Jefferson University, along with the rest of his team as we move forward with these ground-breaking trials.”

The Phase I/II trial for SMD is a prospective, open-label study designed to determine the safety and tolerability of the hESC-derived RPE cells following sub-retinal transplantation into patients with SMD. The trial will ultimately enroll 12 patients, with cohorts of three patients each in an ascending dosage format. Preliminary results relating to both early safety and biological function for the first two patients in the U.S., one SMD patient and one dry AMD patient, were recently reported in The Lancet.

Specific patient enrollment for both trials at the Wills Eye Institute will be determined in the near future. Further information about patient eligibility for the SMD study and the concurrent study on dry AMD is also available on http://www.clinicaltrials.gov; ClinicalTrials.gov Identifiers: NCT01345006 and NCT01344993.

About Stargardt's Disease

Stargardt’s disease or Stargardt’s Macular Dystrophy is a genetic disease that causes progressive vision loss, usually starting in children between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium.

About hESC-derived RPE Cells

The retinal pigment epithelium (RPE) is a highly specialized tissue located between the choroids and the neural retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

About Wills Eye Institute

Wills Eye Institute is a global leader in ophthalmology, established in 1832 as the nation’s first hospital specializing in eye care. U.S. News & World Report has consistently ranked Wills Eye as one of America’s top three ophthalmology centers since the survey began in 1990. Wills Eye is a premier training site for all levels of medical education. Its resident and post-graduate training programs are among the most competitive in the country. One of the core strengths of Wills is the close connection between innovative research and advanced patient care. Wills provides the full range of primary and subspecialty eye care for improving and preserving sight, including cataract, cornea, retina, emergency care, glaucoma, neuro-ophthalmology, ocular oncology, oculoplastics, pathology, pediatric ophthalmology and ocular genetics, refractive surgery and retina. Ocular Services include the Wills Laser Correction Center, Low Vision Service, and Diagnostic Center. Its 24/7 Emergency Service is the only one of its kind in the region. Wills Eye also has a network of nine multi-specialty, ambulatory surgery centers throughout the tri-state area. To learn more, please visit http://www.willseye.org.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2010. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.

Read more:
Advanced Cell Technology Announces Approval of Wills Eye Institute as Additional Site for Stem Cell Clinical Trial for ...

Read More...

Bone Marrow Stem Cells Help Heal Heart Attack Damage

February 15th, 2012 12:53 pm

Featured Article
Academic Journal
Main Category: Stem Cell Research
Also Included In: Cardiovascular / Cardiology
Article Date: 15 Feb 2012 - 2:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public: Healthcare Prof:
A systematic review of the evidence so far suggests stem cells derived from bone marrow moderately improves heart function after a heart attack. But the authors say larger trials are needed before we can devise guidelines for therapy practice, or draw conclusions about the long-term benefit of the treatment, such as whether it extends life.

The review, about to be published in the Cochrane Library, updates one done in 2008 that reviewed 13 trials; the new one takes into account another 20 more recent trials. Even though these later trials had longer follow ups, it was still not possible to draw firm conclusions about the long term benefits.

Lead author Enca Martin-Rendon, of the Stem Cell Research laboratory, NHS Blood and Transplant at the John Radcliffe Hospital in Oxford, UK, told the press that they found it hard to compare the 33 studies because they used so many different approaches:

"Larger trials with standardised treatment procedures would help us to know whether this treatment is really effective," said Martin-Rendon.

In order to pump blood around the body, the heart also needs its own constant supply of blood. If this supply is cut off by a blocked artery, it can cause a heart attack and damage the muscle tissue in the affected part of the heart, causing the cells to start dying, a process known as necrosis.

In the days and weeks after a heart attack, the necrosis can spread, eventually leaving a large part of the heart muscle unable to perform the job of contracting and pumping as well as it ought to. This increases the risk of further heart problems.

Stem cells are precursor cells that have the potential to mature into any cell in the body, including heart muscle cells. For this review, the researchers looked only at treatments that use stem cells derived from bone marrow. At present, such treatments are only available at centres that do research.

Another recently published study described a treatment that used stem cells derived from the patient's own heart tissue to repair heart attack damage.

For the review, Martin-Rendon and colleagues pooled data on a total of 1,765 patients from 33 trials. All the patients had already undergone the conventional treatment, angioplasty, where a balloon is inflated in the blocked artery to open it up and restore blood flow.

They concluded that stem cell therapy using bone marrow-derived stem cells (BMSCs) can result in a moderate long-term improvement in heart function, that lasts for up to 5 years. But there was not enough data to enable them to say anything firm about the effect on survival rates.

Martin-Rendon said:

"This new treatment may lead to moderate improvement in heart function over standard treatments," adding that:

"Stem cell therapy may also reduce the number of patients who later die or suffer from heart failure, but currently there is a lack of statistically significant evidence based on the small number of patients treated so far."

The authors said it was still to early to compile guidelines for standard practice, and further work would be needed before anyone can do this. For instance, more information is needed to establish cell dosage, the timing of transplantation and how best to measure heart function.

One large trial, called BAMI, is already under way. The European Society of Cardiology for Stem Cells and Cardiac Repair is conducting the trial, which is funded by the European Union Seventh Framework Programme for Research and Innovation (EU FP7-BAMI).

Anthony Mathur, a co-author of this latest Cochrane review, and principal investigator of the BAMI trial, said:

''The BAMI trial will be the largest stem cell therapy trial in patients who have suffered heart attacks and will test whether this treatment prolongs the life of these patients."

Written by Catharine Paddock PhD
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our stem cell research section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Catharine Paddock PhD. "Bone Marrow Stem Cells Help Heal Heart Attack Damage." Medical News Today. MediLexicon, Intl., 15 Feb. 2012. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/articles/241658.php&gt;

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Link:
Bone Marrow Stem Cells Help Heal Heart Attack Damage

Read More...

Bioheart to Present at BioFlorida's Saturday Exchange

February 15th, 2012 12:53 pm

SUNRISE, Fla., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Bioheart (BHRT.OB), a leader in developing stem cell therapies to treat cardiovascular diseases, today announced that they have been chosen as a presenter in the BioFlorida Saturday Exchange conference later this month.

The Saturday Exchange is a reprise of the successful Biomed Exchange meeting, held for many years during the 1980-90's. Well over 100 life science professionals gathered in Miami on a Saturday morning each month to learn about various aspects of the community's growing life sciences cluster. The Exchange will take place at University of Miami's Life Science & Technology Park.

The Keynote Speaker is Bioheart's Chairman William P. Murphy Jr., MD. Dr. Murphy will share his career experiences and insights as a leading entrepreneur in the medical device industry, spanning the founding of Cordis Corporation to more recent ventures. In addition, Mike Tomas, Bioheart's president and CEO and Kristin Comella, Bioheart's CSO will present the use of stem cells in degenerative diseases

"The Saturday Exchange brings together many professionals to discuss the field of biotechnology," said Mike Tomas. "Bioheart is excited about the opportunity to represent the South Florida community and share our experiences in the field of regenerative medicine."

About Bioheart

Bioheart (BHRT.OB) is committed to developing stem cell therapies to treat congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other medical problems. The company focuses on the discovery and development of therapies that will improve patients' quality of life and reduce health care costs and hospitalizations. Bioheart's leading product, MyoCell, is a muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart to improve cardiac function.

For more information on Bioheart, visit http://www.bioheartinc.com.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

Read the original here:
Bioheart to Present at BioFlorida's Saturday Exchange

Read More...

First local dogs receive ‘amazing’ stem-cell therapy

February 15th, 2012 12:51 pm

Just before 10 a.m. Tuesday, Jake — a hobbling, 12-year-old yellow Labrador retriever — went into surgery at the Stanley Veterinary Clinic in Overland Park with crippling arthritis, no longer able to run without pain or even walk down stairs.

He had already been on months of medications that seemed to turn the normally happy dog sad. And hip and joint replacements costing tens of thousands of dollars were not feasible, said owners Mike and Elizabeth LeBlanc of Leawood.Still, their 8-year-old daughter, Mia, had just one request at Christmas. “All I want is for Jake to feel better,” she wrote.So, on Tuesday morning, Jake became one of the first canines in the Kansas City area to undergo a somewhat new and controversial procedure in which stem cells were harvested from the fat of his own body and then injected into his joints. The expectation is that within a few weeks the cells will regenerate missing cartilage and turn his arthritic joints healthy again.“It’s amazing,” said veterinarian Les E. Pelfrey, who conducted the procedure. “A few weeks later, these guys are running up and down.”The stem-cell procedure, which has gained notice in recent years with anecdotal stories of success on YouTube and cable television, remains controversial not only for its quick adoption in veterinary clinics nationwide, but also because some researchers say it remains scientifically unproven and expensive, at $1,800 or more per treatment.“Let me tell you one thing,” said James L. Cook, a professor of orthopedics at the University of Missouri’s College of Veterinary Medicine. “I don’t want to write off stem cells. Stem cells may hold the key for truly restorative medicine.”In horses, stems cells have been shown to help rejuvenate damaged tendons and other problems. They are being tested for cardiac problems.“But in the joints for dogs with arthritis? No way,” Cook said. “I would never recommend anyone get this done.”Stem cells essentially are the equivalent of young and impressionable cells whose genetic gears have yet to determine their fate. Because they are so young, they theoretically can turn into any kind of cell, from cartilage to neurons. In humans, stem cells have long been held out as possible therapy for diseases such as Parkinson’s.The problem, Cook said, is that although a few studies have shown that the injection of stem cells into arthritic canine joints does reduce pain, compared with “control” dogs not injected with stems cells, no studies have convincingly shown that stems cells are any better at helping dogs than the current, and less expensive, standard of care. That typically involves a combination of weight loss, pain medications and, when necessary, injections of hyaluronic acid, a slippery substance that often goes missing in arthritis. Those injections, given a couple of times a year, cost less than $100 each.Moreover, even if the stem cells work, no one knows at this point how long the improvement will persist, although some vets have noted benefits lasting a year or more.“We know for sure that it (stem cell injections) does have some palliative effects. It can make symptoms better,” Cook said. “And we do know for sure that it does not regenerate cartilage in arthritic joints. The palliative effects are not as good, or no better, than hyaluronic acid injections.”That is far from the case being made by companies now promoting stem-cell therapy in dogs, or owners who believe in it.A number of stem-cell companies have emerged in recent years. Chief among them are Vet-Stem, based in Poway, Calif., and MediVet America, a division of MediVet, based in Sydney, Australia, which notes that it is currently conducting studies on canines, stem cells and cartilage regeneration.Both use largely similar technologies and methods. At the vet’s office, the dog undergoes a quick procedure in which a bolus of fat about the size of a golf ball is taken from above the shoulder.The fat is processed and treated with chemicals to extract millions of stem cells. Some of those cells are then injected into a dog’s damaged joints; the rest enter the body through an intravenous line into the bloodstream.One prime difference between the Vet-Stem and MediVet systems is that Vet-Stem costs about $3,000 or more.Vet-Stem requires the veterinarian to ship the fat sample to California, where it is processed and sent back for injection. Several dogs in the Kansas City area have been injected with stem cells from Vet-Stem.The MediVet system costs pet owners about $1,800. It provides veterinarians with a kit to process the stem cells in their own offices over about four hours. Dogs are injected with stems cells on the same day the fat is removed. The pet typically goes home the next day.In Topeka, the University Bird and Small Animal Clinic has used the MediVet kit and system with what it says are positive results on about 40 dogs since November 2010. A veterinarian there, Larry Snyder, helped train Pelfrey in Overland Park.Snyder came to the clinic two weeks ago to perform the procedure on another hobbled yellow Labrador retriever, Milo, owned by dentist Jon Finley and his wife, Sharon, in Leawood.“Dr. Pelfrey and Mrs. Finley didn’t tell me how much this procedure was going to cost,” Jon Finley said, “and I’d rather you not tell me. No matter what, he’s walking better, standing upright, feeling better. I can’t help but think he’s going to get better and better.”Jake’s owner said that, whatever the outcome, she knows that the procedure is not a cure.“I’m hoping this gives him a better quality of life,” Elizabeth LeBlanc said. “I got him when he was just 6 weeks old. He was such a blessing. It will be worth it, even if I can give him one more great summer.”

To reach Eric Adler, call 816-234-4431 or send email to eadler@kcstar.com.

View post:
First local dogs receive ‘amazing’ stem-cell therapy

Read More...

Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling …

February 15th, 2012 12:50 pm

Dentists can be at the forefront of the emerging field of regenerative medicine by offering Store-A-Tooth™ dental stem cell banking.

This service enables families to save their own adult stem cells from teeth that are naturally coming out or being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

Provia Laboratories, LLC will be exhibiting its Store-A-Tooth™ dental stem cell preservation service during the Chicago Midwinter Meeting at booth # 3346.

Lexington, MA (PRWEB) February 15, 2012

Provia Laboratories, LLC will be exhibiting during the Chicago Midwinter Meeting at booth # 3346 to showcase its Store-A-Tooth™ dental stem cell preservation service.

The Store-A-Tooth service enables families to save their own adult stem cells – from baby teeth ready to fall out; teeth pulled for orthodontic reasons; and wisdom teeth being extracted. Dental professionals play a role in making patients aware of this option, giving families the choice to safely and securely store their stem cells today – in a convenient and affordable way – so that they can take advantage of future therapies in regenerative medicine and dentistry.

The company partners with dental offices to make it easy to educate and inform patients about the option to preserve their family’s dental stem cells. For those interested in the service, Provia works with the dental team to provide high quality tooth collection, and arranges for the sample to be sent overnight to the lab, where the stem cells are harvested, tested and cryopreserved for future potential use.

“New stem cell therapies are going to change medicine as we know it, and dentists will play a leading role in enabling this transformation,” states Howard Greenman, Provia Labs CEO. “There’s been a lot of media buzz about stem cell research in general, but most people are unaware that a very potent and plentiful source of viable stem cells exits in the dental pulp of healthy teeth.”

Dental stem cells have already successfully been used in people to regenerate alveolar jaw bone and to treat periodontal disease. “One of the first routine applications in the oral cavity for the use of mesenchymal stem cells from teeth will be to promote bone growth around implants so they integrate more quickly, similar to how cellular bone matrix products are used today,” says Dr. Nicholas Perrotta, DMD, who started providing the Store-A-Tooth service in 2011.

“In addition to potential applications in regenerative dentistry, dental stem cell research may lead to new treatments for a wide range of medical conditions, including type 1 diabetes, stroke, cardiovascular disease, spinal cord injuries, and Parkinson’s disease, to name a few,” explains Peter Verlander, PhD, Chief Scientific Officer for Provia Labs. “Dental stem cell collection and preservation gives parents the peace of mind that they are now equipped to take advantage of the breakthroughs in stem cell therapies that will arise from the research community.”

“Store-A-Tooth is less expensive than collecting stem cells from umbilical cord blood. In fact, we hear from many of our customers that they are thankful to have this opportunity to store their stem cells, especially if they missed the chance to save cord blood,” states Greenman. “Our mission is to make stem cell banking accessible to the millions of children losing teeth every year.”

There are no fees or costs to dentists who wish to become an authorized Store-A-Tooth provider; in fact dentists can generate incremental revenue for assisting with tooth collection. Provia Labs supplies all participating practices with patient education materials, practice tools and dedicated support; training is simple and there is minimal impact to existing workflow.

Dental professionals share Store-A-Tooth educational materials with their patients, who enroll directly with Provia Labs. The day of the appointment, the dentist simply places the extracted tooth into the Store-A-Tooth collection kit, which includes a proven transport device called Save-A-Tooth®. In use by thousands of dentists for over 20 years, the Save-A-Tooth is an FDA-approved and ADA-accepted device for transporting avulsed teeth for reimplantation. The Store-A-Tooth collection kit is shipped overnight to the Provia Laboratories facility, where the stem cells are processed and stored.

The Store-A-Tooth service is currently available to dental offices throughout the United States and internationally. To become a provider, visit http://www.store-a-tooth.com or call 877-867-5753.

About Provia Laboratories, LLC

Headquartered in Lexington, MA, Provia Laboratories, LLC (http://www.provialabs.com) is a healthcare services company specializing in high quality biobanking (preservation of biological specimens). The company’s Store-A-Tooth™ service platform enables the collection, transport, processing, and storage of dental stem cells for potential use in future stem-cell therapies. The company advises industrial, academic, and governmental clients on matters related to the preservation of biological specimens for research and clinical use. In addition, Provia offers a variety of products for use in complex biobanking environments to improve sample logistics, security, and quality. For more information on dental stem cells, call 1-877-867-5753, visit http://www.store-a-tooth.com or http://www.facebook.com/storeatooth, or follow via twitter @StoreATooth.

###

Store-A-Tooth
Provia Laboratories, LLC
877-867-5753
Email Information

Read more:
Provia Labs Makes Chicago Midwinter Meeting Debut and Launches Store-A-Tooth™ Dental Stem Cell Preservation, Enabling ...

Read More...

Page 1,509«..1020..1,5081,5091,5101,511..1,5201,530..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick